Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.
about
Getting the balance right: Established and emerging therapies for major depressive disordersDuloxetine in the treatment of stress urinary incontinencePrediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy.Duloxetine in the treatment of generalized anxiety disorder.Continuation treatment of major depressive disorder: is there a case for duloxetine?Pharmacological agents for the treatment of urinary incontinence due to overactive bladder.Duloxetine for the management of fibromyalgia syndrome.New and emerging therapeutic agents for the treatment of fibromyalgia: an update.Duloxetine in the treatment of chronic pain due to fibromyalgia and diabetic neuropathyDuloxetine for the treatment of fibromyalgia.Duloxetine in the treatment of major psychiatric and neuropathic disorders.Duloxetine: a serotonin-noradrenaline re-uptake inhibitor for the treatment of stress urinary incontinence.Effect of age on the pharmacokinetics of duloxetine in women.Efficacy of duloxetine on painful physical symptoms in major depressive disorder for patients with clinically significant painful physical symptoms at baseline: a meta-analysis of 11 double-blind, placebo-controlled clinical trials.Duloxetine: a dual reuptake inhibitor.Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder.Duloxetine: a new selective and dual-acting antidepressant.Duloxetine: A New Treatment for the Emotional and Physical Symptoms of Depression.Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.Pharmacokinetics and Safety of Duloxetine Enteric-coated Tablets in Chinese Healthy Volunteers: A Randomized, Open-label, Single- and Multiple-dose Study.The role of duloxetine in the treatment of anxiety disorders.Duloxetine for the treatment of generalized anxiety disorder: a review.Efficacy and safety of duloxetine 60 mg once daily in major depressive disorder: a review with expert commentaryDuloxetine: clinical pharmacokinetics and drug interactions.Use of cerebrospinal fluid biomarkers in clinical trials for schizophrenia and depression.Duloxetine: a review of its use in the management of major depressive disorder in older adults.Acute and subacute effects of the selective serotonin-noradrenaline reuptake inhibitor duloxetine on cardiac hERG channels.Preparation and evaluation of enteric-coated delayed-release pellets of duloxetine hydrochloride using a fluidized bed coater.Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans.Duloxetine HCl lipid nanoparticles: preparation, characterization, and dosage form design.Clinical outcome and tolerability of duloxetine in the treatment of major depressive disorder: a 12-week study with plasma levels.Comparative safety and tolerability of duloxetine vs. pregabalin vs. duloxetine plus gabapentin in patients with diabetic peripheral neuropathic pain.Duloxetine in the treatment of stress urinary incontinence.Seizures during antidepressant treatment in psychiatric inpatients--results from the transnational pharmacovigilance project "Arzneimittelsicherheit in der Psychiatrie" (AMSP) 1993-2008.Identification of 5-HT(2C) mediated mechanisms involved in urethral sphincter reflexes in a guinea-pig model of urethral function.Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.Non-fatal overdose of duloxetine in combination with other antidepressants and benzodiazepines.Duloxetine in elderly major depression disorder: effectiveness and drug plasma level evaluation.Acute massive pulmonary thromboembolism due to acute intoxication by duloxetine: a case report.Levomilnacipran: A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.
P2860
Q24610225-79396042-FA3F-45F2-81BD-3CE967E0A756Q24680252-8760FDC7-3664-4772-AC81-3322AB5E2BB8Q33716001-881B0D21-F60F-46E9-896B-F55726ADB14BQ33735030-217EB4D5-EB56-4C62-B32F-08B2FB7F71ABQ33755767-867E594E-2452-47C6-A1D5-B0CDAB7367CFQ34104589-3B023D1D-3644-4B34-B819-7A77DCF5750CQ34418217-282D1FCD-E028-4B1E-B099-184A49E692A6Q34418303-7A2B2C20-97D1-46C5-9CF6-5D59ADC71556Q34623747-FF07375C-7BD8-4E1E-B8FB-0137CE3F894AQ34663934-FCB50C23-EC9A-43C0-B3A2-27E0A22DE331Q34770302-55B303C8-F92C-4197-9A89-A84CB5C38CC3Q35207634-69A224A1-0DD7-4279-936C-9FBC1D36218DQ35825909-9D1E8378-BB9E-4656-BFD1-69C14C342A43Q35833315-29555917-65A6-47BC-9D51-828191E3445BQ35937708-50AAEC94-BEA8-41A7-BCD6-A1CFD5171C13Q36103337-CF3CBA05-E288-4F0D-A49A-6C78B0745F24Q36407366-493AB7AC-9959-42B8-AD4D-5904D619AFF5Q36489025-BC7A81A9-DE5E-4788-BDE6-15146B869297Q36637666-D589472A-1E5B-46C7-9793-FFC71DFAD24BQ36832344-BF091C66-16F9-4827-A9CC-7D61C08C51AAQ37062590-0D6F5AD4-FE35-4B38-AA50-E7824722BF5FQ37224580-200FBC35-A160-4A7E-972F-73FCA09EDB9DQ37449200-E78180BE-2744-4E63-9BAE-E49B435C35F5Q37848815-D5D5BEC8-5B33-4601-8197-DBDD5CB07328Q37980501-77CB0DD3-508E-47B0-AC66-5BED5EF332EAQ38067355-C41D5C84-C456-488F-A045-E9D9F4A7A093Q39153130-E8A0D502-24DA-4E2C-A200-19D27AD6CB5EQ40727561-BE98A61C-0150-43C6-ADA6-492AE2707BE5Q40901122-DC006724-98F9-46FF-92A3-3AB1AF2EC7BDQ41988425-F8E6252E-1F2B-4D4A-A236-C6BE1EEA1E56Q42619331-EA6F94EE-FD09-4804-B338-CC702C6C6365Q42660985-9523BF7C-8012-4D38-B05B-938C81923FBBQ43267071-D2CD9960-DADB-404A-ABF4-D9CB62F4BA0DQ43800445-142B9621-5D9E-46ED-AEA6-143B48EF2C1DQ44278308-655DF42F-5FAE-4913-8A90-57629CA75B2CQ44464099-8A95873B-EA98-4407-89E7-60BDAFD13F99Q46495711-5836E025-A2FE-4B8B-B59D-4C0D38E94EDFQ47984936-A03F01F2-7DAA-4719-A3B8-31C06E99E0B6Q48257418-40BE3612-21EC-4526-B8E9-6B4673DC9356Q48298082-F0B03B9F-B7EE-4A48-B3EA-34BE32579C42
P2860
Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Pharmacokinetics and safety of ...... pinephrine reuptake inhibitor.
@en
Pharmacokinetics and safety of ...... pinephrine reuptake inhibitor.
@nl
type
label
Pharmacokinetics and safety of ...... pinephrine reuptake inhibitor.
@en
Pharmacokinetics and safety of ...... pinephrine reuptake inhibitor.
@nl
prefLabel
Pharmacokinetics and safety of ...... pinephrine reuptake inhibitor.
@en
Pharmacokinetics and safety of ...... pinephrine reuptake inhibitor.
@nl
P2093
P2860
P1476
Pharmacokinetics and safety of ...... pinephrine reuptake inhibitor.
@en
P2093
Cerimele BJ
Goldberg MJ
P2860
P304
P356
10.1177/00912700022008810
P577
2000-02-01T00:00:00Z